Use of our validated algorithm that characterizes entire courses of systemic therapy treatment in patients diagnosed with breast, colorectal, and lung cancer will allow researchers in a variety of settings to conduct comparative effectiveness studies related to the uptake, safety, outcomes, and costs associated with the use of both novel and standard regimens.
No takes yet. Share an insight, caveat, or question.
Carroll et al. (2017) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: